Cargando…
Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome
Mycobacterium tuberculosis is responsible for the greatest number of deaths worldwide due to a bacterial agent. We recently identified bortezomib (Velcade; compound 1) as a promising antituberculosis (anti-TB) compound. We showed that compound 1 inhibits the mycobacterial caseinolytic proteases P1 a...
Autores principales: | Moreira, Wilfried, Santhanakrishnan, Sridhar, Ngan, Grace J. Y., Low, Choon Bing, Sangthongpitag, Kanda, Poulsen, Anders, Dymock, Brian W., Dick, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404560/ https://www.ncbi.nlm.nih.gov/pubmed/28193668 http://dx.doi.org/10.1128/AAC.02307-16 |
Ejemplares similares
-
Assembly and proteolytic processing of mycobacterial ClpP1 and ClpP2
por: Benaroudj, Nadia, et al.
Publicado: (2011) -
Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome
por: Moreira, Wilfried, et al.
Publicado: (2017) -
Mycobacterium tuberculosis ClpP1 and ClpP2 Function Together in Protein Degradation and Are Required for Viability in vitro and During Infection
por: Raju, Ravikiran M., et al.
Publicado: (2012) -
ClpAP proteolysis does not require rotation of the ClpA unfoldase relative to ClpP
por: Kim, Sora, et al.
Publicado: (2020) -
Human CLPP reverts the longevity phenotype of a fungal ClpP deletion strain
por: Fischer, Fabian, et al.
Publicado: (2013)